Oncology:  The patient was greater than three weeks out of high-dose ARA-C chemotherapy and her total granulocyte count recovered by [**2154-12-30**] to greater than 1000.
A bone marrow biopsy was performed [**2155-1-1**] for reassessment of response to chemotherapy.
The patient is to follow up with Dr. [**Last Name (STitle) **] for a second round of high-dose ARA-C chemotherapy starting [**2155-1-6**].
Infectious Disease:  The patient was afebrile throughout the period covered by this dictation, and cefepime and acyclovir were discontinued on [**2154-12-30**].
AmBisome 180 mg every 24 hours was continued.
The Infectious Disease team was reconsulted for recommendations concerning course of AmBisome therapy given that the patient had already completed a full six-week course.
As these lesions are thought to be candidal in origin, the Infectious Disease team recommended an additional six weeks of AmBisome therapy starting from [**2154-12-30**], when ANC counts reached greater than 1000.
It is the Infectious Disease team's feeling that the patient will need intravenous AmBisome concurrent with all future chemotherapy treatments.
For fever workup due to temperature spike on [**2154-12-26**], viral cultures from nasal washings returned negative for RSV and influenza virus.
Neurology:  Patient initially presented to [**Hospital1 346**] on [**2154-11-17**] for intracranial hemorrhage to the right frontal and mid-brain area.
If leukemic involvement of CNS is discovered, this will alter future chemotherapy regimens, and possibly include intrathecal chemotherapy.
They recommended a rehabilitation facility for continued high-level balance activities and increased safety awareness and increase in function.
She was initially resistant to rehabilitation placement, however, with encouragement from the family and advice from the medical team, she eventually agreed to transfer to rehabilitation.
Status post high-dose ARA-C 7.
AmBisome 180 mg intravenously every 24 hours for six weeks starting [**2154-12-30**] 2.
Senna one tablet once daily 3.
Peridex 15 cc twice a day 4.
Nystatin 5 cc four times a day 5.
Ativan 0.5 to 1.0 mg intravenously as needed 6.
Tylenol 325 to 650 mg as needed 7.
Magnesium oxide 400 mg by mouth once daily  DISCHARGE INSTRUCTIONS: 1.
The patient is to follow up with Dr. [**First Name4 (NamePattern1) **] [**Last Name (NamePattern1) **], Oncology, for high-dose ARA-C chemotherapy starting [**2155-1-6**].
The patient is to follow up with Dr. [**First Name8 (NamePattern2) **] [**Last Name (NamePattern1) 724**] in Infectious Disease upon completion of AmBisome therapy.
